Bronchoscopic lung volume reduction for patients with emphysema

Completed

• Conditions: COPD - heterogeneous emphysema; Respiratory; Emphysema

• Registration Number: ISRCTN04761234
• Lead Sponsor: Imperial College London (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-02-29
• Last Update Posted: 20 November 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

1. Adult patients with stable severe COPD (GOLD stage III or IV with FEV1<50%pred)
2. Medical Research Council (MRC) dyspnoea score between 3 and 5
3. Total lung capacity (TLC)>100%predicted, residual volume (RV)>150% predicted
4. Six minute walk distance of <450m
5. Patients will be on optimum medical therapy including inhaled corticosteroids and long acting beta 2 agonist and anti-cholinergic agents unless they are intolerant or decline to use them
6. CT thorax must demonstrate heterogeneous emphysema with a defined target lobe with lung destruction and intact adjacent interlobar fissures. Scans will be reviewed by 2 radiologists independently and a third will adjudicate on any disagreements. Radiologists will have to agree that the worst affected lobe of the lung has an emphysema score of >2 (according to the NETT study scoring system), that it is at least 1 point higher than ipsilateral lobes and that it has intact fissures visible on at least one projection

Exclusion Criteria

1. Significant co morbidity which limits their exercise capacity or prognosis
2. Significant daily sputum production
3. Hypoxia (i.e. PO2<6.5Pa)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The percentage change in post-bronchodilator FEV1 measured 90 days post procedure.